IQVIA launches AI models to predict clinical trial outcomes

IQVIA (NYSE: IQV) introduced IQVIA Life Science Models at its TechIQ 2026 event, a suite of AI-based tools designed to help life sciences companies predict clinical trial outcomes.

The models are built using Nvidia Nemotron technology and run on Amazon Web Services infrastructure. They combine molecular and treatment data with patient journey information to support predictive applications in clinical development.

Key capabilities include clinical study simulation and protocol optimization, covering endpoint selection, patient eligibility criteria, dose selection, and sample size planning. In an initial evaluation across 50 trials and 270 endpoints, the company said 85% of predictions were on target or clinically close.

The product also includes digital twins and synthetic controls intended to support more efficient study designs, as well as tools to inform real-world planning based on clinical study predictions.

According to the company's press release, the models extend IQVIA's existing Predictive Clinical Development approach, allowing sponsors to simulate studies and test assumptions before execution.

You May Also Be Interested In

• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
• Jazz Pharmaceuticals' Ziihera shows 3-year survival data in GEA
• Genmab's Rina-S meets phase 3 endpoints in ovarian cancer trial